Complementing this, a synthetic LRP antagonist, RRP‐Dkk1c is developed, which exhibits heightened effectiveness in attenuating Wnt/β‐catenin signaling activity compared to Dkk1, thereby abolishing the formation of CT26‐derived colon cancer xenograft in vivo. The gene discussed is DDX53; the disease is malignant colon neoplasm.